Evaluation of anticancer medicinal products in man

  • Email
  • Help
Current effective version

Revision 4 - Adopted guideline

Currently under revision - see below

Reference numberCHMP/205/95 Rev. 4
Published11/01/2013
Effective from01/07/2013
KeywordsCancer, malignancy, biomarker, targeted drugs, pharmacogenomics
DescriptionThis document provides guidance on the clinical development for the treatment of malignancies, including drug resistance modifiers or normal tissue protective compounds. Read together with answers from the CHMP SAG for Oncology for revision of the anticancer guideline.


Document history

Revision 5

In progress

Adopted guideline

 

 

Draft guideline



Concept paper

Published: 20/11/2017

Effective from: 01/04/2018

 

Published: 15/03/2016

Deadline for comments: 15/09/2016


Published: 30/04/2015

Revision 4 

Current version

Adopted guideline


Draft guideline


Concept paper

In operation: 01/07/2013–present


Published: 22/12/2011


Published: 17/09/2010

Revision 3Adopted guidelineIn operation: 01/06/2006-01/07/2013


Related content


 

How helpful is this page?

Average rating:

 Based on 2 ratings

Add your rating:

See all ratings
0 ratings
0 ratings
0 ratings
0 ratings
2 ratings
    

Tell us more